Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 9/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | GCKR | Q14397 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29621133 | 1.00 | PDE2A (0.41) | PDE2AKDM4ENPSR1KIF11ALDH1A1 | |
| SCHEMBL26847586 | 0.84 | PDE2A (0.41) | PDE2AKDM4ENPSR1KIF11ALDH1A1 | |
| SCHEMBL22925836 | 0.79 | PDE2A (0.40) | PDE2AKDM4ENPSR1KIF11ALDH1A1 | |
| SCHEMBL25407644 | 0.79 | CSNK1D (0.40) | ALDH1A1KMT2A | |
| SCHEMBL4681659 | 0.79 | NPY5R (0.46) | KDM4ENPSR1KIF11ALDH1A1KMT2A | |
| SCHEMBL30567666 | 0.79 | CSNK1D (0.40) | ALDH1A1KMT2A | |
| SCHEMBL29595709 | 0.77 | NPSR1 (0.53) | KDM4ENPSR1KIF11KMT2ATRPV3 | |
| SCHEMBL811160 | 0.77 | NPSR1 (0.53) | KDM4ENPSR1KIF11KMT2ATRPV3 | |
| SCHEMBL15048498 | 0.76 | GRM5 (0.40) | KDM4ENPSR1ALDH1A1KMT2ABACE1 | |
| SCHEMBL22659826 | 0.74 | NOTUM (0.42) | PDE2AKDM4EBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | PDE2A 2451/4885KDM4E 1551/4885NPSR1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.